- Report
- January 2022
- 200 Pages
Global
From €7268EUR$7,500USD£6,225GBP
- Report
- January 2022
- 200 Pages
Global
From €7268EUR$7,500USD£6,225GBP
- Report
- January 2022
- 200 Pages
Global
From €7268EUR$7,500USD£6,225GBP
- Report
- January 2022
- 60 Pages
Global
From €3828EUR$3,950USD£3,279GBP
- Report
- February 2023
- 174 Pages
Global
From €2423EUR$2,500USD£2,075GBP
- Report
- August 2022
United States
From €1880EUR$1,940USD£1,610GBP
- Report
- August 2022
Global
From €1153EUR$1,190USD£988GBP
- Report
- February 2021
Global
From €2869EUR$2,960USD£2,457GBP
- Report
- August 2021
Europe
From €3314EUR$3,420USD£2,839GBP
- Report
- August 2021
Global
From €3867EUR$3,990USD£3,312GBP
- Report
- January 2023
- 123 Pages
Global
From €3387EUR$3,495USD£2,901GBP
- Drug Pipelines
- December 2022
- 36 Pages
Global
From €9686EUR$9,995USD£8,296GBP
- Report
- June 2019
- 44 Pages
Global
From €3872EUR$3,995USD£3,316GBP
- Drug Pipelines
- November 2020
- 3999 Pages
Global
From €2423EUR$2,500USD£2,075GBP
- Report
- January 2022
- 80 Pages
Africa
From €3678EUR$3,795USD£3,150GBP
- Report
- January 2022
- 40 Pages
India
From €2515EUR$2,595USD£2,154GBP
- Report
- January 2022
- 40 Pages
Saudi Arabia
From €2515EUR$2,595USD£2,154GBP
- Report
- June 2023
- 93 Pages
Global
From €3500EUR$3,869USD£3,103GBP
- Report
- October 2022
- 1814 Pages
Global
From €1938EUR$2,000USD£1,660GBP
- Report
- April 2021
- 220 Pages
Global
From €2423EUR$2,500USD£2,075GBP
The Non Hodgkin Lymphoma Drug market is a subset of the larger Lymphoma Drugs market. Non Hodgkin Lymphoma (NHL) is a type of cancer that affects the lymphatic system, and is the seventh most common cancer in the United States. Treatment for NHL typically involves chemotherapy, radiation, and targeted therapies. The Non Hodgkin Lymphoma Drug market is composed of a variety of drugs used to treat NHL, including monoclonal antibodies, small molecule drugs, and immunomodulators. These drugs are used to target specific proteins and pathways involved in the development and progression of NHL.
Some of the major companies in the Non Hodgkin Lymphoma Drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Merck, Novartis, Pfizer, and Roche. Show Less Read more